低血清丸激素作为尿道狭窄的不良预后标志物:单中心前性纵向研究
Soumya Mondal1, Amitayu Jana1, Debansu Sarkar1
1Urology, Institute of Post Graduate Medical Education & Research, Kolkata, IND.
Cureus
|May 27, 2024
概括
男性的低丸激素水平与尿道狭窄疾病的较差结果有关,包括更长的狭窄和更高的复发率. 这一发现凸显了激素健康在治疗这种疾病中的重要性.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 内分泌学 在内分泌学.
- 安德罗学与人类学
背景情况:
- 雄激素对阴茎健康至关重要,影响血管性和组织完整性.
- 低丸激素 (性阴性) 可能会对尿道狭窄的严重程度和治疗结果产生负面影响.
研究的目的:
- 研究激素水平,特别是和非创伤性尿道狭窄的临床结果之间的关联.
- 为了比较患有尿道狭窄的患者和没有尿道狭窄的患者的荷尔蒙特征.
主要方法:
- 一项前性纵向研究,将40名尿道狭窄患者与40名对照人进行比较.
- 排除具有明显荷尔蒙异常或瘤的患者.
- 测量血清丸激素,FSH,LH和TSH水平;评估低雄性恋 (丸激素<300 ng/dL) 以及其与缩长度,严重程度和6个月内复发的相关性.
主要成果:
- 与对照组相比,尿道狭窄患者的平均水平 (386 ng/dL vs. 660 ng/dL) 显著降低.
- 在狭窄症患者中观察到较高的性质下降症发病率 (47.5%对27.5%).
- 较低的丸激素在长段 (>2厘米) 和泛前部收缩中更为普遍;复发与较低的丸激素 (272 ng/dL与440 ng/dL) 相关.
结论:
- 低血清丸激素与尿道狭窄患者的较差结果有关.
- 阴性腺症与收缩的长度增加和复发风险增加相关,这强调了丸激素水平在治疗尿道收缩疾病中的临床意义.
相关概念视频
Disorders of the Male Reproductive System
395
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
395
Infertility in Males
260
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
260
Testosterone: Functions and Regulation
633
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
633


